B lymphocytes as therapeutic targets in systemic lupus erythematosus (Q36653646)

15 August 2017

1 reference

title

B lymphocytes as therapeutic targets in systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

15 August 2017

main subject

0 references

author name string

Paul Hasler

series ordinal

1 reference

15 August 2017

Moncef Zouali

series ordinal

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Therapeutic Targets

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

803-815

1 reference

Azathioprine therapy for patients with systemic lupus erythematosus

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

B-lymphocytes, innate immunity, and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Pathogenic autoantibodies: emerging insights into tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

B cell targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

CD40‐CD40 ligand interaction in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Tumor necrosis factor in the serum of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Renal expression of IL-6 and TNFalpha genes in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

BAFF AND APRIL: a tutorial on B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

B cell diversity and longevity in systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

BAFF production by antigen-presenting cells provides T cell co-stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Store-operated cation entry mediated by CD20 in membrane rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

The epitope recognized by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Treatment of SLE with anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Caspase-independent killing of Burkitt lymphoma cell lines by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Modification of accessory molecule signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Hyperresponsive B cells in CD22-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

CD22 regulates thymus-independent responses and the lifespan of B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.803

10.1517/14728222.10.6.803

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference